Alzinova: Our view of the aducanumab failure

Research Note

2019-03-22

09:05

Eisai and Biogen today announced the decision to discontinue the global phase III trials, ENGAGE and EMERGE, that was designed to measure efficacy and safety of aducanumab. We are somewhat surprised that any information would get presented at this time. Of the failed phase III trials with Aβ immunotherapies so far, aducanumab is most similar to ALZ-101, although there are distinct differences as well. But from this point of view, it is to be seen as negative news. However, there was limited information on today’s decision to discontinue development with aducanumab. Investors should hence take a cautious stance until more information presents.

AH

Anders Hedlund

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.